Report cover image

Global Microneedle Flu Vaccine Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 191 Pages
SKU # APRC20360029

Description

Summary

According to APO Research, the global Microneedle Flu Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Microneedle Flu Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Microneedle Flu Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Microneedle Flu Vaccine market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Microneedle Flu Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Microneedle Flu Vaccine market include Sanofi, NanoPass Technologies, Microdermics and OraSure Technologies, GC Pharma, FluGen, Debiotech, CosMED Pharmaceuticals, Corium International and Becton Dickinson and Company, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Microneedle Flu Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Microneedle Flu Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Microneedle Flu Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Microneedle Flu Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Microneedle Flu Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Microneedle Flu Vaccine sales, projected growth trends, production technology, application and end-user industry.

Microneedle Flu Vaccine Segment by Company

Sanofi
NanoPass Technologies
Microdermics and OraSure Technologies
GC Pharma
FluGen
Debiotech
CosMED Pharmaceuticals
Corium International
Becton Dickinson and Company
Microneedle Flu Vaccine Segment by Type

Hollow Microneedle
Coated Microneedle
Solid Microneedle
Dissolving Microneedle
Microneedle Flu Vaccine Segment by Application

Influenza A
Influenza B
Microneedle Flu Vaccine Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Microneedle Flu Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Microneedle Flu Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Microneedle Flu Vaccine significant trends, drivers, influence factors in global and regions.
6. To analyze Microneedle Flu Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microneedle Flu Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Microneedle Flu Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microneedle Flu Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Microneedle Flu Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Microneedle Flu Vaccine industry.
Chapter 3: Detailed analysis of Microneedle Flu Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Microneedle Flu Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Microneedle Flu Vaccine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Table of Contents

191 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Microneedle Flu Vaccine Sales Value (2020-2031)
1.2.2 Global Microneedle Flu Vaccine Sales Volume (2020-2031)
1.2.3 Global Microneedle Flu Vaccine Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Microneedle Flu Vaccine Market Dynamics
2.1 Microneedle Flu Vaccine Industry Trends
2.2 Microneedle Flu Vaccine Industry Drivers
2.3 Microneedle Flu Vaccine Industry Opportunities and Challenges
2.4 Microneedle Flu Vaccine Industry Restraints
3 Microneedle Flu Vaccine Market by Company
3.1 Global Microneedle Flu Vaccine Company Revenue Ranking in 2024
3.2 Global Microneedle Flu Vaccine Revenue by Company (2020-2025)
3.3 Global Microneedle Flu Vaccine Sales Volume by Company (2020-2025)
3.4 Global Microneedle Flu Vaccine Average Price by Company (2020-2025)
3.5 Global Microneedle Flu Vaccine Company Ranking (2023-2025)
3.6 Global Microneedle Flu Vaccine Company Manufacturing Base and Headquarters
3.7 Global Microneedle Flu Vaccine Company Product Type and Application
3.8 Global Microneedle Flu Vaccine Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Microneedle Flu Vaccine Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Microneedle Flu Vaccine Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Microneedle Flu Vaccine Market by Type
4.1 Microneedle Flu Vaccine Type Introduction
4.1.1 Hollow Microneedle
4.1.2 Coated Microneedle
4.1.3 Solid Microneedle
4.1.4 Dissolving Microneedle
4.2 Global Microneedle Flu Vaccine Sales Volume by Type
4.2.1 Global Microneedle Flu Vaccine Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Microneedle Flu Vaccine Sales Volume by Type (2020-2031)
4.2.3 Global Microneedle Flu Vaccine Sales Volume Share by Type (2020-2031)
4.3 Global Microneedle Flu Vaccine Sales Value by Type
4.3.1 Global Microneedle Flu Vaccine Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Microneedle Flu Vaccine Sales Value by Type (2020-2031)
4.3.3 Global Microneedle Flu Vaccine Sales Value Share by Type (2020-2031)
5 Microneedle Flu Vaccine Market by Application
5.1 Microneedle Flu Vaccine Application Introduction
5.1.1 Influenza A
5.1.2 Influenza B
5.2 Global Microneedle Flu Vaccine Sales Volume by Application
5.2.1 Global Microneedle Flu Vaccine Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Microneedle Flu Vaccine Sales Volume by Application (2020-2031)
5.2.3 Global Microneedle Flu Vaccine Sales Volume Share by Application (2020-2031)
5.3 Global Microneedle Flu Vaccine Sales Value by Application
5.3.1 Global Microneedle Flu Vaccine Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Microneedle Flu Vaccine Sales Value by Application (2020-2031)
5.3.3 Global Microneedle Flu Vaccine Sales Value Share by Application (2020-2031)
6 Microneedle Flu Vaccine Regional Sales and Value Analysis
6.1 Global Microneedle Flu Vaccine Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Microneedle Flu Vaccine Sales by Region (2020-2031)
6.2.1 Global Microneedle Flu Vaccine Sales by Region: 2020-2025
6.2.2 Global Microneedle Flu Vaccine Sales by Region (2026-2031)
6.3 Global Microneedle Flu Vaccine Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Microneedle Flu Vaccine Sales Value by Region (2020-2031)
6.4.1 Global Microneedle Flu Vaccine Sales Value by Region: 2020-2025
6.4.2 Global Microneedle Flu Vaccine Sales Value by Region (2026-2031)
6.5 Global Microneedle Flu Vaccine Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Microneedle Flu Vaccine Sales Value (2020-2031)
6.6.2 North America Microneedle Flu Vaccine Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Microneedle Flu Vaccine Sales Value (2020-2031)
6.7.2 Europe Microneedle Flu Vaccine Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Microneedle Flu Vaccine Sales Value (2020-2031)
6.8.2 Asia-Pacific Microneedle Flu Vaccine Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Microneedle Flu Vaccine Sales Value (2020-2031)
6.9.2 South America Microneedle Flu Vaccine Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Microneedle Flu Vaccine Sales Value (2020-2031)
6.10.2 Middle East & Africa Microneedle Flu Vaccine Sales Value Share by Country, 2024 VS 2031
7 Microneedle Flu Vaccine Country-level Sales and Value Analysis
7.1 Global Microneedle Flu Vaccine Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Microneedle Flu Vaccine Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Microneedle Flu Vaccine Sales by Country (2020-2031)
7.3.1 Global Microneedle Flu Vaccine Sales by Country (2020-2025)
7.3.2 Global Microneedle Flu Vaccine Sales by Country (2026-2031)
7.4 Global Microneedle Flu Vaccine Sales Value by Country (2020-2031)
7.4.1 Global Microneedle Flu Vaccine Sales Value by Country (2020-2025)
7.4.2 Global Microneedle Flu Vaccine Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Microneedle Flu Vaccine Sales Value Growth Rate (2020-2031)
7.5.2 USA Microneedle Flu Vaccine Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Microneedle Flu Vaccine Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Microneedle Flu Vaccine Sales Value Growth Rate (2020-2031)
7.6.2 Canada Microneedle Flu Vaccine Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Microneedle Flu Vaccine Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Microneedle Flu Vaccine Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Microneedle Flu Vaccine Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Microneedle Flu Vaccine Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Microneedle Flu Vaccine Sales Value Growth Rate (2020-2031)
7.8.2 Germany Microneedle Flu Vaccine Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Microneedle Flu Vaccine Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Microneedle Flu Vaccine Sales Value Growth Rate (2020-2031)
7.9.2 France Microneedle Flu Vaccine Sales Value Share by Type, 2024 VS 2031
7.9.3 France Microneedle Flu Vaccine Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Microneedle Flu Vaccine Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Microneedle Flu Vaccine Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Microneedle Flu Vaccine Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Microneedle Flu Vaccine Sales Value Growth Rate (2020-2031)
7.11.2 Italy Microneedle Flu Vaccine Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Microneedle Flu Vaccine Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Microneedle Flu Vaccine Sales Value Growth Rate (2020-2031)
7.12.2 Spain Microneedle Flu Vaccine Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Microneedle Flu Vaccine Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Microneedle Flu Vaccine Sales Value Growth Rate (2020-2031)
7.13.2 Russia Microneedle Flu Vaccine Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Microneedle Flu Vaccine Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Microneedle Flu Vaccine Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Microneedle Flu Vaccine Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Microneedle Flu Vaccine Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Microneedle Flu Vaccine Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Microneedle Flu Vaccine Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Microneedle Flu Vaccine Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Microneedle Flu Vaccine Sales Value Growth Rate (2020-2031)
7.16.2 China Microneedle Flu Vaccine Sales Value Share by Type, 2024 VS 2031
7.16.3 China Microneedle Flu Vaccine Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Microneedle Flu Vaccine Sales Value Growth Rate (2020-2031)
7.17.2 Japan Microneedle Flu Vaccine Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Microneedle Flu Vaccine Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Microneedle Flu Vaccine Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Microneedle Flu Vaccine Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Microneedle Flu Vaccine Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Microneedle Flu Vaccine Sales Value Growth Rate (2020-2031)
7.19.2 India Microneedle Flu Vaccine Sales Value Share by Type, 2024 VS 2031
7.19.3 India Microneedle Flu Vaccine Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Microneedle Flu Vaccine Sales Value Growth Rate (2020-2031)
7.20.2 Australia Microneedle Flu Vaccine Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Microneedle Flu Vaccine Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Microneedle Flu Vaccine Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Microneedle Flu Vaccine Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Microneedle Flu Vaccine Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Microneedle Flu Vaccine Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Microneedle Flu Vaccine Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Microneedle Flu Vaccine Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Microneedle Flu Vaccine Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Microneedle Flu Vaccine Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Microneedle Flu Vaccine Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Microneedle Flu Vaccine Sales Value Growth Rate (2020-2031)
7.24.2 Chile Microneedle Flu Vaccine Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Microneedle Flu Vaccine Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Microneedle Flu Vaccine Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Microneedle Flu Vaccine Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Microneedle Flu Vaccine Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Microneedle Flu Vaccine Sales Value Growth Rate (2020-2031)
7.26.2 Peru Microneedle Flu Vaccine Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Microneedle Flu Vaccine Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Microneedle Flu Vaccine Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Microneedle Flu Vaccine Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Microneedle Flu Vaccine Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Microneedle Flu Vaccine Sales Value Growth Rate (2020-2031)
7.28.2 Israel Microneedle Flu Vaccine Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Microneedle Flu Vaccine Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Microneedle Flu Vaccine Sales Value Growth Rate (2020-2031)
7.29.2 UAE Microneedle Flu Vaccine Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Microneedle Flu Vaccine Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Microneedle Flu Vaccine Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Microneedle Flu Vaccine Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Microneedle Flu Vaccine Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Microneedle Flu Vaccine Sales Value Growth Rate (2020-2031)
7.31.2 Iran Microneedle Flu Vaccine Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Microneedle Flu Vaccine Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Microneedle Flu Vaccine Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Microneedle Flu Vaccine Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Microneedle Flu Vaccine Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Sanofi
8.1.1 Sanofi Comapny Information
8.1.2 Sanofi Business Overview
8.1.3 Sanofi Microneedle Flu Vaccine Sales, Value and Gross Margin (2020-2025)
8.1.4 Sanofi Microneedle Flu Vaccine Product Portfolio
8.1.5 Sanofi Recent Developments
8.2 NanoPass Technologies
8.2.1 NanoPass Technologies Comapny Information
8.2.2 NanoPass Technologies Business Overview
8.2.3 NanoPass Technologies Microneedle Flu Vaccine Sales, Value and Gross Margin (2020-2025)
8.2.4 NanoPass Technologies Microneedle Flu Vaccine Product Portfolio
8.2.5 NanoPass Technologies Recent Developments
8.3 Microdermics and OraSure Technologies
8.3.1 Microdermics and OraSure Technologies Comapny Information
8.3.2 Microdermics and OraSure Technologies Business Overview
8.3.3 Microdermics and OraSure Technologies Microneedle Flu Vaccine Sales, Value and Gross Margin (2020-2025)
8.3.4 Microdermics and OraSure Technologies Microneedle Flu Vaccine Product Portfolio
8.3.5 Microdermics and OraSure Technologies Recent Developments
8.4 GC Pharma
8.4.1 GC Pharma Comapny Information
8.4.2 GC Pharma Business Overview
8.4.3 GC Pharma Microneedle Flu Vaccine Sales, Value and Gross Margin (2020-2025)
8.4.4 GC Pharma Microneedle Flu Vaccine Product Portfolio
8.4.5 GC Pharma Recent Developments
8.5 FluGen
8.5.1 FluGen Comapny Information
8.5.2 FluGen Business Overview
8.5.3 FluGen Microneedle Flu Vaccine Sales, Value and Gross Margin (2020-2025)
8.5.4 FluGen Microneedle Flu Vaccine Product Portfolio
8.5.5 FluGen Recent Developments
8.6 Debiotech
8.6.1 Debiotech Comapny Information
8.6.2 Debiotech Business Overview
8.6.3 Debiotech Microneedle Flu Vaccine Sales, Value and Gross Margin (2020-2025)
8.6.4 Debiotech Microneedle Flu Vaccine Product Portfolio
8.6.5 Debiotech Recent Developments
8.7 CosMED Pharmaceuticals
8.7.1 CosMED Pharmaceuticals Comapny Information
8.7.2 CosMED Pharmaceuticals Business Overview
8.7.3 CosMED Pharmaceuticals Microneedle Flu Vaccine Sales, Value and Gross Margin (2020-2025)
8.7.4 CosMED Pharmaceuticals Microneedle Flu Vaccine Product Portfolio
8.7.5 CosMED Pharmaceuticals Recent Developments
8.8 Corium International
8.8.1 Corium International Comapny Information
8.8.2 Corium International Business Overview
8.8.3 Corium International Microneedle Flu Vaccine Sales, Value and Gross Margin (2020-2025)
8.8.4 Corium International Microneedle Flu Vaccine Product Portfolio
8.8.5 Corium International Recent Developments
8.9 Becton Dickinson and Company
8.9.1 Becton Dickinson and Company Comapny Information
8.9.2 Becton Dickinson and Company Business Overview
8.9.3 Becton Dickinson and Company Microneedle Flu Vaccine Sales, Value and Gross Margin (2020-2025)
8.9.4 Becton Dickinson and Company Microneedle Flu Vaccine Product Portfolio
8.9.5 Becton Dickinson and Company Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Microneedle Flu Vaccine Value Chain Analysis
9.1.1 Microneedle Flu Vaccine Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Microneedle Flu Vaccine Sales Mode & Process
9.2 Microneedle Flu Vaccine Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Microneedle Flu Vaccine Distributors
9.2.3 Microneedle Flu Vaccine Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.